{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:59:23Z","timestamp":1790391563657,"version":"4.1.0"},"reference-count":26,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Ann Clin Transl Neurol"],"abstract":"ABSTRACT<\/jats:title>\n \n Objective<\/jats:title>\n Corroborate blood neuron\u2010derived extracellular vesicle (NDEV) alpha\u2010synuclein (\u03b1Syn), the CSF \u03b1Syn seed amplification assay (\u03b1Syn\u2010SAA), and blood microRNA\u20107\u20105p (miR\u20107\u20105p) as markers for Parkinson's disease (PD) phenoconversion and determine if combining these markers would help select subjects who would be more likely to phenoconvert.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Using Parkinson Progression Marker Initiative data, time to PD phenoconversion was determined by Hoehn and Yahr scores. Log\u2010rank analysis was used to find cutpoints. Cox regression analysis was used with log[miR\u20107\u20105p], log[NDEV \u03b1Syn], and the \u03b1Syn\u2010SAA. Models included age and sex.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n In a Cox model with baseline log[miR\u20107\u20105p], for each unit increase in log[miR\u20107\u20105p], there was 1.57 times increased PD phenoconversion (\n p<\/jats:italic>\n \u2009=\u20090.003). In a model with baseline log[NDEV \u03b1Syn], only baseline age was associated with increased phenoconversion (\n p<\/jats:italic>\n \u2009<\u20090.05). Using Cox regression analysis, the cutpoints for miR\u20107\u20105p and NDEV \u03b1Syn were 27.39 reads per million mapped (\n p<\/jats:italic>\n \u2009<\u20090.01) and 18.36\u2009pg\/mL (\n p<\/jats:italic>\n \u2009=\u20090.01), respectively. In separate models using log[miR\u20107\u20105p] and log[NDEV \u03b1Syn] cutpoints, higher levels of log[miR\u20107\u20105p] and log[NDEV \u03b1Syn] resulted in 2.26 (\n p<\/jats:italic>\n \u2009<\u20090.001) and 4.46 (\n p<\/jats:italic>\n \u2009<\u20090.05) times increased PD phenoconversion, respectively. A positive \u03b1Syn\u2010SAA was associated with 3.62 times increased phenoconversion (\n p<\/jats:italic>\n \u2009<\u20090.001). Having log[miR\u20107\u20105p] higher than its cutpoint and a positive \u03b1Syn\u2010SAA was associated with 4.31 times phenoconversion (\n p<\/jats:italic>\n \u2009<\u20090.001).\n <\/jats:p>\n <\/jats:sec>\n \n Interpretation<\/jats:title>\n Blood miR\u20107\u20105p, NDEV \u03b1Syn, and \u03b1Syn\u2010SAA could be used to enrich for prodromal patients likely to develop PD earlier in disease\u2010modifying clinical trials and combining them could further enrich for this population.<\/jats:p>\n <\/jats:sec>","DOI":"10.1002\/acn3.70539","type":"journal-article","created":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:05:05Z","timestamp":1790388305000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["microRNA<\/scp>\n \u20107\u20105p and \u03b1\u2010Synuclein\n SAA<\/scp>\n Predict Parkinson's Disease Phenoconversion"],"prefix":"10.1002","author":[{"given":"Shayan","family":"Zadegan","sequence":"first","affiliation":[{"name":"Department of Neurology The University of Tennessee Health Science Center Memphis Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen","family":"Velammal","sequence":"additional","affiliation":[{"name":"Department of Neurology The University of Tennessee Health Science Center Memphis Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanmani","family":"Muthiah","sequence":"additional","affiliation":[{"name":"Department of Neurology The University of Tennessee Health Science Center Memphis Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhu","family":"Jatty","sequence":"additional","affiliation":[{"name":"Department of Neurology The University of Tennessee Health Science Center Memphis Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8847-2501","authenticated-orcid":false,"given":"Christopher","family":"Adams","sequence":"additional","affiliation":[{"name":"Department of Neurology The University of Tennessee Health Science Center Memphis Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","article-title":"Global, Regional, and National Burden of Parkinson's Disease, 1990\u20132016: A Systematic Analysis for the Global Burden of Disease Study 2016","volume":"17","author":"Dorsey E. R.","year":"2018","journal-title":"Lancet Neurology"},{"key":"e_1_2_11_3_1","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S1474-4422(17)30299-5","article-title":"Global, Regional, and National Burden of Neurological Disorders During 1990\u20132015: A Systematic Analysis for the Global Burden of Disease Study 2015","volume":"16","author":"Feigin V. L.","year":"2017","journal-title":"Lancet Neurology"},{"key":"e_1_2_11_4_1","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-080952","article-title":"Projections for Prevalence of Parkinson's Disease and Its Driving Factors in 195 Countries and Territories to 2050: Modelling Study of Global Burden of Disease Study 2021","volume":"388","author":"Su D.","year":"2025","journal-title":"BMJ"},{"key":"e_1_2_11_5_1","doi-asserted-by":"crossref","first-page":"405","DOI":"10.18553\/jmcp.2022.28.4.405","article-title":"The Economic Burden of Parkinson Disease Among Medicare Beneficiaries","volume":"28","author":"Albarmawi H.","year":"2022","journal-title":"Journal of Managed Care & Specialty Pharmacy"},{"key":"e_1_2_11_6_1","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1186\/s12916-023-02933-4","article-title":"Caregiver Burden in Parkinson's Disease: A Mixed\u2010Methods Study","volume":"21","author":"Geerlings A. D.","year":"2023","journal-title":"BMC Medicine"},{"key":"e_1_2_11_7_1","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/ana.21995","article-title":"Clinical Progression in Parkinson Disease and the Neurobiology of Axons","volume":"67","author":"Cheng H. C.","year":"2010","journal-title":"Annals of Neurology"},{"key":"e_1_2_11_8_1","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000210279","article-title":"Alpha\u2010Synuclein Seed Amplification Assay Amplification Parameters and the Risk of Progression in Prodromal Parkinson Disease","volume":"104","author":"Coughlin D. G.","year":"2025","journal-title":"Neurology"},{"key":"e_1_2_11_9_1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s40820-021-00753-w","article-title":"Multiplexed Profiling of Extracellular Vesicles for Biomarker Development","volume":"14","author":"Jiang C.","year":"2021","journal-title":"Nano\u2010Micro Letters"},{"key":"e_1_2_11_10_1","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1002\/mds.28591","article-title":"Validation of \u03b1Synuclein in L1CAM\u2010Immunocaptured Exosomes as a Biomarker for the Stratification of Parkinsonian Syndromes","volume":"36","author":"Jiang C.","year":"2021","journal-title":"Movement Disorders"},{"key":"e_1_2_11_11_1","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/jamaneurol.2023.4398","article-title":"Neuronally Derived Extracellular Vesicle Alpha\u2010Synuclein as a Serum Biomarker for Individuals at Risk of Developing Parkinson Disease","volume":"81","author":"Yan S.","year":"2024","journal-title":"JAMA Neurology"},{"key":"e_1_2_11_12_1","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.neulet.2018.05.009","article-title":"MicroRNA\u20107 Facilitates the Degradation of Alpha\u2010Synuclein and Its Aggregates by Promoting Autophagy","volume":"678","author":"Choi D. C.","year":"2018","journal-title":"Neuroscience Letters"},{"key":"e_1_2_11_13_1","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1007\/s13311-021-01130-6","article-title":"MicroRNA\u20107 Protects Against Neurodegeneration Induced by Alpha\u2010Synuclein Preformed Fibrils in the Mouse Brain","volume":"18","author":"Zhang J.","year":"2021","journal-title":"Neurotherapeutics"},{"key":"e_1_2_11_14_1","doi-asserted-by":"crossref","first-page":"13052","DOI":"10.1073\/pnas.0906277106","article-title":"Repression of Alpha\u2010Synuclein Expression and Toxicity by microRNA\u20107","volume":"106","author":"Junn E.","year":"2009","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"e_1_2_11_15_1","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13024-016-0094-3","article-title":"MicroRNA\u20107 Targets Nod\u2010Like Receptor Protein 3 Inflammasome to Modulate Neuroinflammation in the Pathogenesis of Parkinson's Disease","volume":"11","author":"Zhou Y.","year":"2016","journal-title":"Molecular Neurodegeneration"},{"key":"e_1_2_11_16_1","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1016\/j.ymthe.2017.08.017","article-title":"Loss of MicroRNA\u20107 Regulation Leads to \u03b1Synuclein Accumulation and Dopaminergic Neuronal Loss In\u00a0Vivo","volume":"25","author":"McMillan K. J.","year":"2017","journal-title":"Molecular Therapy"},{"key":"e_1_2_11_17_1","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s43587-021-00042-6","article-title":"Deep Sequencing of sncRNAs Reveals Hallmarks and Regulatory Modules of the Transcriptome During Parkinson's Disease Progression","volume":"1","author":"Kern F.","year":"2021","journal-title":"Nature Aging"},{"key":"e_1_2_11_18_1","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2026.1784013","article-title":"Retrospective Longitudinal Analysis of Blood microRNA\u20107\u20105p as a Possible Progression Biomarker in People With Parkinson's Disease","volume":"20","author":"Zadegan S. A.","year":"2026","journal-title":"Frontiers in Neuroscience"},{"key":"e_1_2_11_19_1","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41531-023-00628-4","article-title":"Candidate Biomarkers of EV\u2010microRNA in Detecting REM Sleep Behavior Disorder and Parkinson's Disease","volume":"10","author":"Li Y.","year":"2024","journal-title":"npj Parkinson's Disease"},{"key":"e_1_2_11_20_1","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/s41596-022-00787-3","article-title":"Seed Amplification Assay for the Detection of Pathologic Alpha\u2010Synuclein Aggregates in Cerebrospinal Fluid","volume":"18","author":"Concha\u2010Marambio L.","year":"2023","journal-title":"Nature Protocols"},{"key":"e_1_2_11_21_1","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/mdc3.13687","article-title":"Striatal Dopamine Loss in Early Parkinson's Disease: Systematic Review and Novel Analysis of Dopamine Transporter Imaging","volume":"10","author":"Heng N.","year":"2023","journal-title":"Movement Disorders Clinical Practice"},{"key":"e_1_2_11_22_1","doi-asserted-by":"crossref","first-page":"12726","DOI":"10.1074\/jbc.M109.086827","article-title":"Post\u2010Transcriptional Regulation of Alpha\u2010Synuclein Expression by Mir\u20107 and Mir\u2010153","volume":"285","author":"Doxakis E.","year":"2010","journal-title":"Journal of Biological Chemistry"},{"key":"e_1_2_11_23_1","doi-asserted-by":"crossref","first-page":"12725","DOI":"10.1523\/JNEUROSCI.0985-14.2014","article-title":"MicroRNA\u20107 Protects Against 1\u2010Methyl\u20104\u2010Phenylpyridinium\u2010Induced Cell Death by Targeting RelA","volume":"34","author":"Choi D. C.","year":"2014","journal-title":"Journal of Neuroscience"},{"key":"e_1_2_11_24_1","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1007\/s11064-018-2638-0","article-title":"Signature of Aberrantly Expressed microRNAs in the Striatum of Rotenone\u2010Induced Parkinsonian Rats","volume":"43","author":"Horst C. H.","year":"2018","journal-title":"Neurochemical Research"},{"key":"e_1_2_11_25_1","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.chemosphere.2019.05.064","article-title":"Identification of miRNA\u20107 as a Regulator of Brain\u2010Derived Neurotrophic Factor\/Alpha\u2010Synuclein Axis in Atrazine\u2010Induced Parkinson's Disease by Peripheral Blood and Brain microRNA Profiling","volume":"233","author":"Li B.","year":"2019","journal-title":"Chemosphere"},{"key":"e_1_2_11_26_1","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41531-025-01083-z","article-title":"A Novel Approach to Detecting Plasma Synuclein Aggregates for Parkinson's Disease Diagnosis","volume":"11","author":"Ko H. R.","year":"2025","journal-title":"npj Parkinson's Disease"},{"key":"e_1_2_11_27_1","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12459","article-title":"Single\u2010Extracellular Vesicle (EV) Analyses Validate the Use of L1 Cell Adhesion Molecule (L1CAM) as a Reliable Biomarker of Neuron\u2010Derived EVs","volume":"13","author":"Nogueras\u2010Ortiz C. J.","year":"2024","journal-title":"Journal of Extracellular Vesicles"}],"container-title":["Annals of Clinical and Translational Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acn3.70539","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/acn3.70539","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acn3.70539","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:05:09Z","timestamp":1790388309000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/acn3.70539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":26,"alternative-id":["10.1002\/acn3.70539"],"URL":"https:\/\/doi.org\/10.1002\/acn3.70539","archive":["Portico"],"relation":{},"ISSN":["2328-9503","2328-9503"],"issn-type":[{"value":"2328-9503","type":"print"},{"value":"2328-9503","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"assertion":[{"value":"2026-07-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"acn3.70539"}}